Semaglutide Quick Start
Semaglutide is the active drug in Ozempic, Wegovy, and Rybelsus. Their approved indications, formulations, and dose schedules differ. A dose in one product cannot be assumed equivalent to the same number of milligrams in another, especially across oral and injectable forms.
Semaglutide is a GLP-1 receptor agonist. It acts on a gut-hormone pathway involved in blood sugar and appetite. Approved injections are weekly; approved tablets are daily. This guide separates the Wegovy injection example, selected oral-product schedules, and research-vial arithmetic.
Two routes
Injectable (once weekly) and oral tablet (once daily). The two routes use different dose schedules.
Slow start
Wegovy injection uses four-week escalation stages; the oral schedules below use 30-day stages. Further steps depend on the exact product label and tolerability.
Calculation only
At a nominal 2.5 mg/mL, 0.25 mg equals 0.10 mL or 10 U-100 units. Research-vial math does not establish a sterile or approved product.
Long half-life
About 7 days. Steady levels take roughly 4-5 weeks at each dose.
Status
FDA-approved. Research-use vials from supplier sources are for research only.
Educational reference only
This page is an educational research guide. It is not medical advice and is not a treatment plan. Talk to a qualified clinician before starting any peptide.
Semaglutide Dosing Protocol & Schedule
There is no single semaglutide schedule. The injection tab shows the standard Wegovy 2.4 mg target for adult weight reduction, with other maintenance options explained below. The tablet tab covers Wegovy oral and Rybelsus; oral Ozempic is a separate product whose schedule is not tabulated here. Tablets are taken daily, but dose increases occur in 30-day stages, not daily.
Semaglutide Dosing Schedules by Route
Choose a product-specific prescribing-information example. These schedules do not apply to research-grade powders.
Wegovy injection for adult weight reduction: the standard 2.4 mg target, with indication-specific alternatives explained below.
Wegovy Injection: Standard 2.4 mg Target
The table shows Wegovy injection’s standard path to 2.4 mg weekly for adult weight reduction. Each escalation stage lasts four weeks; the label allows delaying an increase for tolerability. The table does not show every maintenance option. See Wegovy prescribing information, sections 2.2–2.3.
Wegovy injection: adult weight reduction, standard 2.4 mg target
Phase
Phase 1 - Initiation
Weeks
Weeks 1-4
Weekly dose
0.25 mg
Label context
Initiation dose; not a maintenance dose.
Phase
Phase 2 - Early escalation
Weeks
Weeks 5-8
Weekly dose
0.5 mg
Label context
Escalation step in this Wegovy example.
Phase
Phase 3 - Mid escalation
Weeks
Weeks 9-12
Weekly dose
1.0 mg
Label context
Escalation step; Ozempic has separate prescribing instructions.
Phase
Phase 4 - High escalation
Weeks
Weeks 13-16
Weekly dose
1.7 mg
Label context
Escalation step toward 2.4 mg; also an adult weight-reduction maintenance option.
Phase
Phase 5 - Maintenance
Weeks
Week 17+
Weekly dose
2.4 mg
Label context
Recommended standard adult weight-reduction maintenance dose; not the maximum for every indication.
| Phase | Weeks | Weekly dose | Label context |
|---|---|---|---|
| Phase 1 - Initiation | Weeks 1-4 | 0.25 mg | Initiation dose; not a maintenance dose. |
| Phase 2 - Early escalation | Weeks 5-8 | 0.5 mg | Escalation step in this Wegovy example. |
| Phase 3 - Mid escalation | Weeks 9-12 | 1.0 mg | Escalation step; Ozempic has separate prescribing instructions. |
| Phase 4 - High escalation | Weeks 13-16 | 1.7 mg | Escalation step toward 2.4 mg; also an adult weight-reduction maintenance option. |
| Phase 5 - Maintenance | Week 17+ | 2.4 mg | Recommended standard adult weight-reduction maintenance dose; not the maximum for every indication. |
Adult weight-reduction maintenance can be 1.7 or 2.4 mg weekly. A later increase to 7.2 mg is optional only after at least 4 weeks tolerated at 2.4 mg when additional weight reduction is clinically indicated. Do not transfer that option to other indications or pediatric use.
Titration Notes
- Titration pacing matters. Slow dose increases reduce stomach side effects. In the STEP trials, side effects were most common during escalation and usually settled by week 20.
- Adult weight reduction. Maintenance may be 1.7 or 2.4 mg weekly, with 2.4 mg recommended. After at least 4 weeks tolerated at 2.4 mg, 7.2 mg may be used if additional weight reduction is clinically indicated. It is optional, not a required final step.
- Other Wegovy injection indications. Adult cardiovascular risk reduction and weight reduction in pediatric patients ages 12–17 use 1.7 or 2.4 mg maintenance. MASH uses 2.4 mg; if not tolerated, the label permits 1.7 mg with consideration of re-escalation. The 7.2 mg option applies only to adult weight reduction.
- Slower escalation. If an escalation dose is not tolerated, the label allows delaying the increase for four weeks.
- Missed dose guidance. FDA labeling states that when the next scheduled dose is more than 2 days away, a missed dose may be taken as soon as possible. When fewer than 2 days remain, the missed dose is skipped and the weekly schedule is maintained. This reports label guidance, not a personal recommendation.
- Ozempic injection differs. Start at 0.25 mg weekly for four weeks, then 0.5 mg. If further glycemic control is needed, increase to 1 mg after at least four weeks at 0.5 mg, then to 2 mg after at least four weeks at 1 mg. The injection maximum is 2 mg; other approved indication details remain product-specific.
Separate research-vial math
The Pep Pal calculator converts nominal mass and volume into U-100 units. It does not convert a research powder into an approved medicine or validate human dosing.
Product-specific daily-tablet schedules for Rybelsus and Wegovy. Oral Ozempic is a separate formulation not tabulated here.
Oral Tablet Titration
The tables below cover Rybelsus 3/7/14 mg and Wegovy tablets 1.5/4/9/25 mg. A separate Ozempic tablet 1.5/4/9 mg formulation also exists; its schedule is outside these tables. Oral products are not substitutable milligram for milligram. Follow the exact product label. These tablets are taken on an empty stomach with no more than 4 oz of plain water, followed by at least 30 minutes before food, drink, or other oral medicines.
Wegovy 25 mg pill titration (obesity)
Phase
Phase 1
Days
Days 1–30
Daily dose
1.5 mg
Notes
Starting dose. Tolerability only.
Phase
Phase 2
Days
Days 31–60
Daily dose
4 mg
Notes
First step up.
Phase
Phase 3
Days
Days 61–90
Daily dose
9 mg
Notes
Mid-range dose.
Phase
Phase 4
Days
Day 91 onward
Daily dose
25 mg
Notes
Maintenance dose for this oral Wegovy schedule.
| Phase | Days | Daily dose | Notes |
|---|---|---|---|
| Phase 1 | Days 1–30 | 1.5 mg | Starting dose. Tolerability only. |
| Phase 2 | Days 31–60 | 4 mg | First step up. |
| Phase 3 | Days 61–90 | 9 mg | Mid-range dose. |
| Phase 4 | Day 91 onward | 25 mg | Maintenance dose for this oral Wegovy schedule. |
Take on an empty stomach with up to 4 oz of plain water. Wait 30 minutes before food, drink, or other oral medication.
Rybelsus titration (type 2 diabetes)
Phase
Phase 1
Duration
Days 1–30
Daily dose
3 mg
Notes
Initiation dose; not effective for glycemic control.
Phase
Phase 2
Duration
Days 31–60
Daily dose
7 mg
Notes
First therapeutic dose. May stay here for ongoing T2D control.
Phase
Phase 3
Duration
Day 61 onward, if needed
Daily dose
14 mg
Notes
Optional increase if additional glycemic control is needed; maximum 14 mg daily.
| Phase | Duration | Daily dose | Notes |
|---|---|---|---|
| Phase 1 | Days 1–30 | 3 mg | Initiation dose; not effective for glycemic control. |
| Phase 2 | Days 31–60 | 7 mg | First therapeutic dose. May stay here for ongoing T2D control. |
| Phase 3 | Day 61 onward, if needed | 14 mg | Optional increase if additional glycemic control is needed; maximum 14 mg daily. |
From day 61, continue 7 mg or increase to 14 mg if additional glycemic control is needed. Rybelsus, oral Ozempic, and oral Wegovy are separate products; their milligram doses are not interchangeable.
Oral absorption is fragile
Oral semaglutide absorption is low and product-specific. Follow the exact tablet’s empty-stomach and waiting-time instructions; food and drink can change absorption.
Treatment-duration context
Product-specific escalation and ongoing treatment
Product example
Standard obesity titration
Escalation context
About 16 weeks to 2.4 mg
Maintenance
Ongoing weekly maintenance
Scope
Approved Wegovy injection example; not research-vial instructions
Product example
Standard T2D titration
Escalation context
About 8-16 weeks to 1.0 or 2.0 mg
Maintenance
Ongoing weekly maintenance
Scope
Approved Ozempic injection; increases depend on glycemic need
Product example
Delayed escalation
Escalation context
Wegovy label permits a four-week delay for tolerability
Maintenance
Maintenance selected for indication and tolerability
Scope
When side effects slow the planned ramp
| Product example | Escalation context | Maintenance | Scope |
|---|---|---|---|
| Standard obesity titration | About 16 weeks to 2.4 mg | Ongoing weekly maintenance | Approved Wegovy injection example; not research-vial instructions |
| Standard T2D titration | About 8-16 weeks to 1.0 or 2.0 mg | Ongoing weekly maintenance | Approved Ozempic injection; increases depend on glycemic need |
| Delayed escalation | Wegovy label permits a four-week delay for tolerability | Maintenance selected for indication and tolerability | When side effects slow the planned ramp |
These medicines are used for ongoing treatment under their product labels. This table does not establish a cycling or off-treatment schedule, or a regimen for research powders.
Semaglutide Supplies Needed
These are theoretical mass-only minima for four weeks each at 0.25, 0.5, 1, and 1.7 mg, then 2.4 mg weekly. The example assumes nominal 10 mg vials at a final 3.0 mL, about 3.33 mg/mL. It does not establish research-vial equivalence to Wegovy or a usable-life claim. The optional 7.2 mg adult regimen is not included.
Recommended Supply
Choose your region
Use discount code SAVE10 at Peptira checkout. See why we love Peptira.
Semaglutide
Pharmacy Grade Semaglutide
At-Home Blood Test
Research Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Peptide Vials (10 mg, 3.33 mg/mL mix)
A nominal 10 mg in a final 3.0 mL gives about 3.33 mg/mL. It contains forty 0.25 mg amounts or four complete 2.4 mg amounts before loss. These are mass counts, not weeks of usable life. Discard dates and unused remnants can require more vials.
| Calculation period | Arithmetic note |
|---|---|
8 weeks 1 vial (mass-only minimum) | Weeks 1–8 total 3 mg; one 10 mg vial is the mass-only minimum, not permission to use one opened vial for 8 weeks. |
16 weeks 2 vials (mass-only minimum) | Weeks 1–16 total 13.8 mg; two 10 mg vials are the mass-only minimum. |
24 weeks 4 vials (mass-only minimum) | Eight additional weeks at 2.4 mg give 33 mg total; four 10 mg vials are the mass-only minimum. |
52 weeks 11 vials (mass-only minimum) | Thirty-six weeks at 2.4 mg after escalation give 100.2 mg total; eleven 10 mg vials are the mass-only minimum. |
8 weeks
1 vial (mass-only minimum)
Weeks 1–8 total 3 mg; one 10 mg vial is the mass-only minimum, not permission to use one opened vial for 8 weeks.
16 weeks
2 vials (mass-only minimum)
Weeks 1–16 total 13.8 mg; two 10 mg vials are the mass-only minimum.
24 weeks
4 vials (mass-only minimum)
Eight additional weeks at 2.4 mg give 33 mg total; four 10 mg vials are the mass-only minimum.
52 weeks
11 vials (mass-only minimum)
Thirty-six weeks at 2.4 mg after escalation give 100.2 mg total; eleven 10 mg vials are the mass-only minimum.
Insulin Syringes (U-100)
Prefer 0.3 mL / 30-unit syringes during the 0.25-1.0 mg phase, and 1.0 mL / 100-unit syringes once doses cross 0.30 mL (30 units).
| Calculation period | Arithmetic note |
|---|---|
8 weeks 8 syringes | 1 syringe per weekly injection. |
16 weeks 16 syringes | 1 per week. Buy a box of 100 to cover the full cycle. |
24 weeks 24 syringes | 1 per week. |
52 weeks 52 syringes | 1 per week. |
8 weeks
8 syringes
1 syringe per weekly injection.
16 weeks
16 syringes
1 per week. Buy a box of 100 to cover the full cycle.
24 weeks
24 syringes
1 per week.
52 weeks
52 syringes
1 per week.
Bacteriostatic Water
Volume arithmetic assumes 3.0 mL per nominal 10 mg vial. Bottle count also depends on the manufacturer’s post-opening discard period and additional vials needed after discard or loss.
| Calculation period | Arithmetic note |
|---|---|
8 weeks 3 mL total | One mass-only vial minimum × 3 mL; bottle count also depends on its discard date. |
16 weeks 6 mL total | Two mass-only vial minima × 3 mL; no opened bottle is assumed usable for 16 weeks. |
24 weeks 12 mL total | Four mass-only vial minima × 3 mL; bottle count also depends on post-opening discard dates. |
52 weeks 33 mL total | Eleven mass-only vial minima × 3 mL; bottle count also depends on post-opening discard dates. |
8 weeks
3 mL total
One mass-only vial minimum × 3 mL; bottle count also depends on its discard date.
16 weeks
6 mL total
Two mass-only vial minima × 3 mL; no opened bottle is assumed usable for 16 weeks.
24 weeks
12 mL total
Four mass-only vial minima × 3 mL; bottle count also depends on post-opening discard dates.
52 weeks
33 mL total
Eleven mass-only vial minima × 3 mL; bottle count also depends on post-opening discard dates.
Actual quantities require validated product-specific storage and discard dates plus unused remnants and handling losses. No generic research-vial beyond-use period is established here. Water-bottle discard dates are separate; the total volume does not establish bottle count across these periods.
Companion Supplies & Routine Support
Semaglutide Reconstitution Calculator
Powered by PepPal
Semaglutide Reconstitution Calculator
Start with the protocol example, then customize every field.
Loaded reference
PDP 5 mg research-vial example
This calculator does not apply to Ozempic or Wegovy pens, or oral semaglutide tablets.
Your draw
10units
0.1 mL on a U-100 insulin syringe
- Concentration
- 2.5 mg/mL
- Target in mg
- 0.25 mg
- Math-only doses per vial
- 20
One free emailed save per person, checked by PepPal.
By submitting your email, you’re signing up for Peptide Dosing Protocols and PepPal updates, supplier deals, and promotional emails. Unsubscribe anytime. Privacy Policy.
Educational calculation tool only. The loaded amount is a reference from this page, not a personal dose recommendation. Confirm the vial label, route, syringe type, and actual liquid added before relying on a result.
Semaglutide Reconstitution Guide
Approved Ozempic and Wegovy injections are finished products and do not use these research-powder calculations. The tables below relate nominal vial mass to an assumed final solution volume. They do not validate a preparation method, diluent, stability, sterility, or human use. A U-100 scale measures volume: 100 units equals 1.0 mL.
Three example concentrations are shown: 2.5, about 3.33, and 5 mg/mL. Higher concentration gives a smaller volume for the same nominal mass. Neither a convenient volume nor a calculator result establishes measurement accuracy or product suitability.
Nominal 2.5 mg/mL concentration example
Vial size
2 mg
Example final volume
0.8 mL
0.25 mg
0.10 mL (10 u)
0.5 mg
0.20 mL (20 u)
1.0 mg
0.40 mL (40 u)
1.7 mg
0.68 mL (68 u)
2.4 mg
Exceeds total vial content
Vial size
3 mg
Example final volume
1.2 mL
0.25 mg
0.10 mL (10 u)
0.5 mg
0.20 mL (20 u)
1.0 mg
0.40 mL (40 u)
1.7 mg
0.68 mL (68 u)
2.4 mg
0.96 mL (96 u)
Vial size
5 mg
Example final volume
2.0 mL
0.25 mg
0.10 mL (10 u)
0.5 mg
0.20 mL (20 u)
1.0 mg
0.40 mL (40 u)
1.7 mg
0.68 mL (68 u)
2.4 mg
0.96 mL (96 u)
| Vial size | Example final volume | 0.25 mg | 0.5 mg | 1.0 mg | 1.7 mg | 2.4 mg |
|---|---|---|---|---|---|---|
| 2 mg | 0.8 mL | 0.10 mL (10 u) | 0.20 mL (20 u) | 0.40 mL (40 u) | 0.68 mL (68 u) | Exceeds total vial content |
| 3 mg | 1.2 mL | 0.10 mL (10 u) | 0.20 mL (20 u) | 0.40 mL (40 u) | 0.68 mL (68 u) | 0.96 mL (96 u) |
| 5 mg | 2.0 mL | 0.10 mL (10 u) | 0.20 mL (20 u) | 0.40 mL (40 u) | 0.68 mL (68 u) | 0.96 mL (96 u) |
u = volume units on a U-100 syringe. One 2 mg vial cannot supply 2.4 mg; a calculated concentration does not override total vial content.
Nominal 3.33 mg/mL example (10 mg in 3.0 mL)
Vial size
10 mg
Example final volume
3.0 mL
0.25 mg
0.075 mL (7.5 u)
0.5 mg
0.15 mL (15 u)
1.0 mg
0.30 mL (30 u)
1.7 mg
0.51 mL (51 u)
2.4 mg
0.72 mL (72 u)
| Vial size | Example final volume | 0.25 mg | 0.5 mg | 1.0 mg | 1.7 mg | 2.4 mg |
|---|---|---|---|---|---|---|
| 10 mg | 3.0 mL | 0.075 mL (7.5 u) | 0.15 mL (15 u) | 0.30 mL (30 u) | 0.51 mL (51 u) | 0.72 mL (72 u) |
Physical vial capacity is product-specific and must be checked separately. A vial’s stated mass does not tell you its capacity.
Nominal 5.0 mg/mL concentration example
Vial size
5 mg
Example final volume
1.0 mL
0.25 mg
0.05 mL (5 u)
0.5 mg
0.10 mL (10 u)
1.0 mg
0.20 mL (20 u)
1.7 mg
0.34 mL (34 u)
2.4 mg
0.48 mL (48 u)
Vial size
10 mg
Example final volume
2.0 mL
0.25 mg
0.05 mL (5 u)
0.5 mg
0.10 mL (10 u)
1.0 mg
0.20 mL (20 u)
1.7 mg
0.34 mL (34 u)
2.4 mg
0.48 mL (48 u)
| Vial size | Example final volume | 0.25 mg | 0.5 mg | 1.0 mg | 1.7 mg | 2.4 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 0.05 mL (5 u) | 0.10 mL (10 u) | 0.20 mL (20 u) | 0.34 mL (34 u) | 0.48 mL (48 u) |
| 10 mg | 2.0 mL | 0.05 mL (5 u) | 0.10 mL (10 u) | 0.20 mL (20 u) | 0.34 mL (34 u) | 0.48 mL (48 u) |
These are mass-to-volume calculations only. Device resolution and capacity must be checked separately; this table does not instruct administration.
Check a concentration calculation
- 01
Identify the product
Approved finished products, compounded preparations, and research powders are separate formulations. Do not transfer their preparation instructions.
- 02
Record mass and final volume
The example of 5 mg in a final 2.0 mL is an arithmetic assumption, not a validated mixing method.
- 03
Calculate concentration
5 mg divided by 2.0 mL equals 2.5 mg/mL.
- 04
Convert the reference amount
0.25 mg divided by 2.5 mg/mL equals 0.10 mL, or 10 U-100 units.
- 05
Check content, capacity, and discard dates
A calculation cannot exceed vial content or device capacity. Product-specific stability, sterility, and discard dates require separate evidence.
Need exact units for a different vial?
Use the free Peptide Reconstitution Calculator. Enter vial size, water volume, and target dose. The calculator returns the exact syringe draw.
Semaglutide Dosage Chart
This chart mirrors the existing Wegovy injection table for adult weight reduction with a standard 2.4 mg target. It is a product-label example, not a universal semaglutide schedule or research-vial instruction. The optional adult 7.2 mg step is explained in the label notes.
How Semaglutide Works
Semaglutide turns on a single target called the GLP-1 receptor. That receptor sits on cells in several different organs, which is why semaglutide affects hunger, blood sugar, the stomach, and the heart all at once.
Two small changes to the natural GLP-1 molecule give semaglutide its long shelf life in the body. First, a tweak in the peptide chain blocks the enzyme (DPP-4) that normally breaks down GLP-1 within minutes. Second, a fatty acid chain lets semaglutide bind to albumin, a protein in the blood. That binding slows clearance and stretches the half-life to about 7 days, which is why one weekly injection is enough.
Brain - appetite and fullness
GLP-1 receptors in the hypothalamus and brainstem signal fullness. Semaglutide turning these on reduces hunger and lowers calories eaten. In STEP 1, participants on 2.4 mg lost an average of 14.9% of body weight over 68 weeks.
Pancreas - glucose-dependent insulin
In the pancreas, semaglutide triggers insulin release - but only when blood sugar is already high. This 'glucose-dependent' behavior makes dangerous low blood sugar much less likely than with some older diabetes drugs. In the SUSTAIN trials, semaglutide cut HbA1c by 1.5-1.9% at the 0.5-1.0 mg doses.
Stomach - slower gastric emptying
Semaglutide slows how fast the stomach empties. That stretches fullness after meals and blunts blood sugar spikes. It also explains the nausea and vomiting that are most common during dose escalation and usually fade with time.
Heart - cardiovascular protection
Semaglutide protects the heart and blood vessels in ways that go beyond weight loss alone. The SELECT trial showed a 20% drop in major heart events (heart attack, stroke, cardiovascular death) in people with obesity and existing heart disease. The benefit appeared even in people who did not lose much weight.
Who Semaglutide Is For and Who Should Avoid It
Semaglutide is FDA-approved for several conditions, but it is not for everyone. Some people should avoid it entirely, and others need close medical oversight before starting.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide carries a boxed warning based on thyroid C-cell tumors in rodent studies.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any ingredient in the formulation.
Use with caution
- Pregnancy and breastfeeding. Semaglutide is not approved for pregnancy. The label recommends stopping at least 2 months before a planned pregnancy because of the long half-life.
- History of pancreatitis. Pancreatitis has been reported in clinical trials. People with prior episodes need clinician oversight.
- Pre-existing diabetic retinopathy. In SUSTAIN-6, retinopathy complications were higher (3.0% vs 1.8% with placebo), likely tied to fast blood-sugar improvement in people who already had retinopathy.
- Gallbladder disease. Gallstones were more common with semaglutide (about 2.6% vs 1.2% with placebo) in the STEP trials, consistent with rapid weight loss in general.
- Severe gastrointestinal disease such as gastroparesis. Semaglutide already slows gastric emptying.
Not medical advice
Eligibility and safety decisions belong with a qualified clinician who knows your full medical history. This page is research reference only.
Semaglutide Side Effects & Safety
The most common side effects of semaglutide are stomach-related: nausea, diarrhea, vomiting, and constipation. They are usually worst during the first few months as the dose increases, and most people find they improve or go away with time. The safety profile below comes from tens of thousands of participants across the STEP, SUSTAIN, and SELECT trial programs.
Common stomach effects
In pooled STEP 1-3 data on the 2.4 mg dose, nausea occurred in 43.9% of participants (vs 16.1% on placebo), diarrhea in 29.7% (vs 15.9%), vomiting in 24.5% (vs 6.3%), and constipation in 24.2% (vs 11.1%). These events were most common during the first 16-20 weeks of escalation and largely passed with time. 99.5% of GI events were non-serious and 98.1% were mild-to-moderate.
Dose-dependent pattern
Lower diabetes doses (0.5-1.0 mg) produced stomach side effects in 32.7-36.4% of participants vs 15.3% on placebo. That is meaningfully lower than the 2.4 mg obesity dose. Higher doses give bigger effects but also more side effects.
Heart rate
Resting heart rate rose by about 1-4 beats per minute in clinical trials. Despite this small increase, SELECT showed a 20% drop in major adverse cardiovascular events in people with existing heart disease and obesity. No rise in heart failure hospitalizations was observed.
Gallbladder and pancreatitis
Gallstones were more common with semaglutide (about 2.6% vs 1.2% with placebo) in STEP, in line with rapid weight loss across all weight-loss interventions. Pancreatitis was rare but reported. Stop and seek care for severe abdominal pain.
Diabetic retinopathy
In SUSTAIN-6 (T2D), retinopathy complications were higher with semaglutide (3.0%) than placebo (1.8%). The most likely cause is fast blood sugar improvement in people who already had retinopathy.
Thyroid boxed warning
Semaglutide carries a boxed warning based on dose-dependent thyroid C-cell tumors in rodent studies. Human relevance is unknown. Semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
Discontinuation
In STEP, 6.8% of people on semaglutide 2.4 mg stopped treatment because of side effects, vs 3.2% on placebo. The most common reasons were nausea (1.8%), vomiting (1.2%), and diarrhea (0.7%).
For a wider safety comparison, see the PepPal Peptide Side Effects Guide.
Semaglutide Timeline & What to Monitor
Semaglutide takes time to build up in the body and time to show meaningful effects. The 7-day half-life means blood levels keep rising for about 4-5 weeks at each dose before they stop changing.
Reasonable timing checkpoints based on clinical trial data
Checkpoint
Weeks 1-4 (0.25 mg)
What clinical trials show
Tolerability phase. No meaningful weight or HbA1c change expected.
Checkpoint
Weeks 5-8 (0.5 mg)
What clinical trials show
Early appetite changes possible. Most stomach side effects show up here.
Checkpoint
Weeks 8-12
What clinical trials show
Appetite suppression often clearly noticeable at 1.0 mg in diabetes research.
Checkpoint
Weeks 16-20
What clinical trials show
Stomach side effects usually plateau. Weight loss curve starts to accelerate.
Checkpoint
Week 28
What clinical trials show
STEP 1 interim data: significant weight loss vs placebo.
Checkpoint
Week 68
What clinical trials show
STEP 1 endpoint: 14.9% mean weight loss at 2.4 mg vs 2.4% placebo.
| Checkpoint | What clinical trials show |
|---|---|
| Weeks 1-4 (0.25 mg) | Tolerability phase. No meaningful weight or HbA1c change expected. |
| Weeks 5-8 (0.5 mg) | Early appetite changes possible. Most stomach side effects show up here. |
| Weeks 8-12 | Appetite suppression often clearly noticeable at 1.0 mg in diabetes research. |
| Weeks 16-20 | Stomach side effects usually plateau. Weight loss curve starts to accelerate. |
| Week 28 | STEP 1 interim data: significant weight loss vs placebo. |
| Week 68 | STEP 1 endpoint: 14.9% mean weight loss at 2.4 mg vs 2.4% placebo. |
These are clinical trial markers, not personal targets.
Markers studied in trials
- Body weight - weekly or monthly trend, not daily.
- HbA1c - 3-month average blood sugar. Used for type 2 diabetes research.
- Fasting glucose - short-term blood sugar marker.
- Blood pressure - SELECT showed small decreases.
- Resting heart rate - small increase (1-4 bpm) is normal.
- Lipid panel - mild improvements in LDL and triglycerides reported in trials.
- Kidney function (eGFR, UACR) - relevant if research touches CKD outcomes (FLOW).
- Liver enzymes - relevant if research touches MASH (ESSENCE).
Lab work belongs with a clinician
Ordering, interpreting, and acting on lab work is a clinical task. This list shows what trials track. It is not a personal monitoring plan.
Semaglutide Clinical Evidence Context
Semaglutide has been studied in more clinical trials than any other GLP-1 medication - over 45,000 participants across multiple programs. Each trial name (STEP, SELECT, FLOW, ESSENCE) is its own program. STEP tested weight loss. SUSTAIN and PIONEER tested diabetes control. SELECT tested heart protection. FLOW tested kidney protection. ESSENCE tested fatty liver disease (MASH). SOUL tested cardiovascular outcomes for oral semaglutide.
Major published semaglutide trials
Trial
STEP 1 (Wilding et al., NEJM 2021)
Design
Phase 3 / 68 weeks
Population
1,961 adults with obesity, no diabetes
Key result
-14.9% body weight (semaglutide 2.4 mg) vs -2.4% placebo. 86.4% reached 5%+ loss.
Trial
STEP 2 (Davies et al., Lancet 2021)
Design
Phase 3 / 68 weeks
Population
1,210 adults with T2D and overweight or obesity
Key result
-9.6% body weight (2.4 mg) vs -3.4% placebo.
Trial
STEP 3 (Wadden et al., JAMA 2021)
Design
Phase 3 / 68 weeks
Population
611 adults with obesity + intensive behavior therapy
Key result
-16.0% body weight (2.4 mg) vs -5.7% placebo.
Trial
STEP 5 (Garvey et al., Nature Med 2022)
Design
Phase 3 / 104 weeks
Population
304 adults with obesity, no diabetes
Key result
-15.2% body weight sustained at 2 years.
Trial
SELECT (Lincoff et al., NEJM 2023)
Design
Phase 3 / 39.8 mo mean follow-up
Population
17,604 adults with CVD + overweight or obesity, no diabetes
Key result
20% reduction in major heart events (HR 0.80; 95% CI 0.72-0.90; P<0.001). -9.4% body weight.
Trial
SUSTAIN-6 (Marso et al., NEJM 2016)
Design
Phase 3 / 104 weeks
Population
3,297 adults with T2D at high CV risk
Key result
26% MACE reduction (HR 0.74; 95% CI 0.58-0.95). First CV signal for semaglutide.
Trial
FLOW (Perkovic et al., NEJM 2024)
Design
Phase 3 / event-driven
Population
3,533 adults with T2D and CKD
Key result
24% reduction in kidney disease progression and CV death (HR 0.76; 95% CI 0.66-0.88).
Trial
ESSENCE (Sanyal et al., NEJM 2025)
Design
Phase 3 / 72 weeks (Part 1)
Population
Adults with MASH, F2-F3 fibrosis
Key result
33% achieved both steatohepatitis resolution and fibrosis improvement vs 16% placebo.
Trial
SOUL (McGuire et al., NEJM 2025)
Design
Phase 3 / event-driven
Population
Adults with T2D + ASCVD or CKD
Key result
Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D.
Trial
STEP TEENS (Weghuber et al., NEJM 2022)
Design
Phase 3 / 68 weeks
Population
201 adolescents (12-17) with obesity
Key result
-16.1% BMI reduction vs +0.6% placebo.
Trial
OASIS 4 (oral Wegovy)
Design
Phase 3 / 64 weeks
Population
Adults with obesity, no diabetes
Key result
-16.6% body weight at 25 mg daily. Basis for Dec 2025 oral Wegovy approval.
| Trial | Design | Population | Key result |
|---|---|---|---|
| STEP 1 (Wilding et al., NEJM 2021) | Phase 3 / 68 weeks | 1,961 adults with obesity, no diabetes | -14.9% body weight (semaglutide 2.4 mg) vs -2.4% placebo. 86.4% reached 5%+ loss. |
| STEP 2 (Davies et al., Lancet 2021) | Phase 3 / 68 weeks | 1,210 adults with T2D and overweight or obesity | -9.6% body weight (2.4 mg) vs -3.4% placebo. |
| STEP 3 (Wadden et al., JAMA 2021) | Phase 3 / 68 weeks | 611 adults with obesity + intensive behavior therapy | -16.0% body weight (2.4 mg) vs -5.7% placebo. |
| STEP 5 (Garvey et al., Nature Med 2022) | Phase 3 / 104 weeks | 304 adults with obesity, no diabetes | -15.2% body weight sustained at 2 years. |
| SELECT (Lincoff et al., NEJM 2023) | Phase 3 / 39.8 mo mean follow-up | 17,604 adults with CVD + overweight or obesity, no diabetes | 20% reduction in major heart events (HR 0.80; 95% CI 0.72-0.90; P<0.001). -9.4% body weight. |
| SUSTAIN-6 (Marso et al., NEJM 2016) | Phase 3 / 104 weeks | 3,297 adults with T2D at high CV risk | 26% MACE reduction (HR 0.74; 95% CI 0.58-0.95). First CV signal for semaglutide. |
| FLOW (Perkovic et al., NEJM 2024) | Phase 3 / event-driven | 3,533 adults with T2D and CKD | 24% reduction in kidney disease progression and CV death (HR 0.76; 95% CI 0.66-0.88). |
| ESSENCE (Sanyal et al., NEJM 2025) | Phase 3 / 72 weeks (Part 1) | Adults with MASH, F2-F3 fibrosis | 33% achieved both steatohepatitis resolution and fibrosis improvement vs 16% placebo. |
| SOUL (McGuire et al., NEJM 2025) | Phase 3 / event-driven | Adults with T2D + ASCVD or CKD | Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D. |
| STEP TEENS (Weghuber et al., NEJM 2022) | Phase 3 / 68 weeks | 201 adolescents (12-17) with obesity | -16.1% BMI reduction vs +0.6% placebo. |
| OASIS 4 (oral Wegovy) | Phase 3 / 64 weeks | Adults with obesity, no diabetes | -16.6% body weight at 25 mg daily. Basis for Dec 2025 oral Wegovy approval. |
ESSENCE Part 2 (240 weeks, liver outcomes) is ongoing, with results expected in 2029.
Semaglutide has the largest clinical evidence base of any GLP-1 receptor agonist. Its FDA label has grown from a single T2D indication in 2017 to six approved indications by early 2026: type 2 diabetes, chronic weight management (injectable and oral), cardiovascular risk reduction, chronic kidney disease protection, and MASH.
Semaglutide Storage & Handling
Storage instructions depend on the exact formulation
Product
Approved injection or tablet
Use these instructions
Its current carton, Instructions for Use, and prescribing information
Limit
Ozempic and Wegovy have different presentations and storage rules. Do not apply one product’s after-opening limit to all pens.
Product
Compounded preparation
Use these instructions
The dispensing pharmacy’s storage instructions and beyond-use date
Limit
Approved-product storage data do not establish compounded-product stability.
Product
Research powder or solution
Use these instructions
Validated product-specific stability and handling data
Limit
No generic 28-day, shipping, refrigerated, or frozen-storage allowance is established here.
Product
Bacteriostatic water
Use these instructions
Manufacturer’s label and post-opening discard instructions
Limit
Its discard date is separate from the peptide solution’s date.
| Product | Use these instructions | Limit |
|---|---|---|
| Approved injection or tablet | Its current carton, Instructions for Use, and prescribing information | Ozempic and Wegovy have different presentations and storage rules. Do not apply one product’s after-opening limit to all pens. |
| Compounded preparation | The dispensing pharmacy’s storage instructions and beyond-use date | Approved-product storage data do not establish compounded-product stability. |
| Research powder or solution | Validated product-specific stability and handling data | No generic 28-day, shipping, refrigerated, or frozen-storage allowance is established here. |
| Bacteriostatic water | Manufacturer’s label and post-opening discard instructions | Its discard date is separate from the peptide solution’s date. |
A clear appearance, preservative, or correct concentration does not establish sterility or stability.
Semaglutide Protocol Mistakes & Troubleshooting
Wrong BAC water volume
Adding the wrong amount of water changes the concentration and the syringe-unit math. For a 5 mg vial, 2.0 mL water = 2.5 mg/mL and 10 units = 0.25 mg. Adding 1.0 mL by mistake doubles the concentration to 5 mg/mL, so 10 units would then equal 0.5 mg - twice the intended starter dose. Recheck the math before drawing.
Cloudy or particulate vial
Do not use a product with unexpected cloudiness, color, or particles. Contact the dispensing pharmacist or manufacturer for the exact product’s instructions. Appearance alone cannot identify the cause or verify sterility, and a clear research solution is not proof that it is safe for human use.
Missed dose
FDA labeling states that when more than 2 days remain before the next scheduled weekly dose, a missed dose may be taken as soon as possible. When fewer than 2 days remain, the missed dose is skipped and the regular weekly schedule resumes without doubling up. This reports label guidance, not a personal recommendation.
Bad nausea during escalation
Stomach side effects can occur during escalation. Wegovy injection labeling allows delaying an increase for four weeks. For adult weight reduction, 1.7 mg is a maintenance option, not merely a temporary reduction; other indications have their own guidance. Dose changes belong with the prescriber. For additional context, see PepPal’s guide to supplements that help with GLP-1 side effects.
Mixing up oral and injectable
Oral and injectable semaglutide have different absorption and dosing. Rybelsus, oral Ozempic, and oral Wegovy also have product-specific formulations. Do not convert between them by milligrams or apply an injectable schedule to a tablet or research powder.
Storage mistakes
Storage and temperature excursions require instructions validated for the exact formulation. No generic research-vial freezing, room-temperature, or refrigerated-storage allowance is established here. A pharmacist or manufacturer can advise on an approved or dispensed product.
Semaglutide Regulatory Status
Semaglutide has one of the broadest FDA approval histories of any modern metabolic drug. As of June 2026, the approved indications are below.
FDA-approved semaglutide brands and indications
Brand
Ozempic (injectable)
Approval date
December 2017
Indication
Type 2 diabetes glycemic control
Brand
Ozempic (injectable)
Approval date
January 2020
Indication
Cardiovascular risk reduction in T2D
Brand
Rybelsus (oral tablet)
Approval date
September 2019
Indication
Type 2 diabetes (first oral GLP-1)
Brand
Wegovy (injectable)
Approval date
June 2021
Indication
Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Brand
Wegovy (injectable)
Approval date
March 2024
Indication
Cardiovascular risk reduction in adults with obesity and CVD
Brand
Wegovy (injectable)
Approval date
August 2025
Indication
Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE)
Brand
Wegovy oral 25 mg pill
Approval date
December 2025
Indication
Chronic weight management (OASIS 4 basis)
Brand
Ozempic (injectable)
Approval date
January 2025
Indication
CKD progression in T2D (FLOW basis)
| Brand | Approval date | Indication |
|---|---|---|
| Ozempic (injectable) | December 2017 | Type 2 diabetes glycemic control |
| Ozempic (injectable) | January 2020 | Cardiovascular risk reduction in T2D |
| Rybelsus (oral tablet) | September 2019 | Type 2 diabetes (first oral GLP-1) |
| Wegovy (injectable) | June 2021 | Chronic weight management (BMI ≥30 or ≥27 with comorbidity) |
| Wegovy (injectable) | March 2024 | Cardiovascular risk reduction in adults with obesity and CVD |
| Wegovy (injectable) | August 2025 | Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE) |
| Wegovy oral 25 mg pill | December 2025 | Chronic weight management (OASIS 4 basis) |
| Ozempic (injectable) | January 2025 | CKD progression in T2D (FLOW basis) |
Research-grade lyophilized semaglutide from supplier sources is not an FDA-approved drug product and is for research use only.
Generics
As of June 2026, no generic semaglutide is FDA-approved in the United States. Novo Nordisk holds the active patents on semaglutide. The FDA-recognized shortage of semaglutide ended in 2025, which limited the legal scope of 503A/503B compounded semaglutide. Some countries have different patent expirations; for example, generic semaglutide is expected to enter the Canadian market earlier than the United States. Verify the current status with FDA orange-book and country-specific regulators.
Semaglutide Cost & Access Context
Semaglutide cost varies a lot depending on the format and the source. Brand pens, compounded pharmacy semaglutide, and research-grade vials sit at very different price points.
Common semaglutide cost brackets (US, June 2026)
Source
Brand Wegovy / Ozempic
Format
Pre-filled pen
Typical cost band
$1,000-$1,400+ per month list price
Notes
Insurance coverage varies. Manufacturer savings cards exist for eligible patients.
Source
Brand Rybelsus
Format
Oral tablet
Typical cost band
Similar to brand pens per month
Notes
Daily dosing. Different mg numbers than injectable.
Source
Compounded pharmacy
Format
Vial or pen
Typical cost band
Highly variable
Notes
Legal scope narrowed after the FDA shortage ended in 2025. Verify the pharmacy is 503A or 503B compliant.
Source
Research-grade lyophilized vial
Format
5 mg or 10 mg vial
Typical cost band
Lower per-mg cost
Notes
Research use only. Not an FDA-approved drug product. Quality depends on the supplier's COA process.
| Source | Format | Typical cost band | Notes |
|---|---|---|---|
| Brand Wegovy / Ozempic | Pre-filled pen | $1,000-$1,400+ per month list price | Insurance coverage varies. Manufacturer savings cards exist for eligible patients. |
| Brand Rybelsus | Oral tablet | Similar to brand pens per month | Daily dosing. Different mg numbers than injectable. |
| Compounded pharmacy | Vial or pen | Highly variable | Legal scope narrowed after the FDA shortage ended in 2025. Verify the pharmacy is 503A or 503B compliant. |
| Research-grade lyophilized vial | 5 mg or 10 mg vial | Lower per-mg cost | Research use only. Not an FDA-approved drug product. Quality depends on the supplier's COA process. |
Prices change. Verify with current supplier and pharmacy quotes before planning.
For a wider supplier comparison and discount-code context, see the PepPal supplier rankings. For per-mg cost math, the PepPal calculator converts vial size and water volume into exact draws.
Semaglutide vs Tirzepatide vs Retatrutide vs Liraglutide
Semaglutide, tirzepatide, and retatrutide are the three most-discussed GLP-1-based compounds for weight management. They activate overlapping but different receptors, which leads to different efficacy levels, side effect profiles, and availability. Liraglutide is the older once-daily GLP-1 that semaglutide replaced for most uses.
Side-by-side comparison
Factor
Receptor targets
Semaglutide
GLP-1 only
Tirzepatide
GLP-1 + GIP
Retatrutide
GLP-1 + GIP + glucagon
Liraglutide
GLP-1 only
Factor
Half-life
Semaglutide
~7 days
Tirzepatide
~5 days
Retatrutide
~6 days
Liraglutide
~13 hours
Factor
Dosing frequency
Semaglutide
Once weekly
Tirzepatide
Once weekly
Retatrutide
Once weekly
Liraglutide
Once daily
Factor
Dose context
Semaglutide
Wegovy: optional 7.2 mg/week only for adult weight reduction under label conditions; oral maximum 25 mg/day
Tirzepatide
15 mg/week adult label maximum; pediatric Mounjaro maximum 10 mg
Retatrutide
12 mg/week highest target in initial TRIUMPH trials
Liraglutide
3.0 mg/day
Factor
Selected trial results; separate studies
Semaglutide
-14.9% at 68 wks (STEP 1)
Tirzepatide
-20.9% at 72 wks (SURMOUNT-1 primary treatment-regimen estimand)
Retatrutide
-28.7% at 68 wks (TRIUMPH-4)
Liraglutide
-8% at 56 wks (SCALE)
Factor
FDA status (June 2026)
Semaglutide
Approved (T2D, obesity, CVD, MASH, CKD, oral)
Tirzepatide
Approved (T2D, obesity)
Retatrutide
Investigational - Phase 3
Liraglutide
Approved (Saxenda obesity, Victoza T2D)
Factor
CV outcomes data
Semaglutide
Yes - SELECT (20% MACE drop)
Tirzepatide
Mounjaro label: major cardiovascular-event risk reduction in high-risk adults with T2D
Retatrutide
Investigational; no approved cardiovascular indication
Liraglutide
Yes - LEADER (13% MACE drop)
| Factor | Semaglutide | Tirzepatide | Retatrutide | Liraglutide |
|---|---|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + glucagon | GLP-1 only |
| Half-life | ~7 days | ~5 days | ~6 days | ~13 hours |
| Dosing frequency | Once weekly | Once weekly | Once weekly | Once daily |
| Dose context | Wegovy: optional 7.2 mg/week only for adult weight reduction under label conditions; oral maximum 25 mg/day | 15 mg/week adult label maximum; pediatric Mounjaro maximum 10 mg | 12 mg/week highest target in initial TRIUMPH trials | 3.0 mg/day |
| Selected trial results; separate studies | -14.9% at 68 wks (STEP 1) | -20.9% at 72 wks (SURMOUNT-1 primary treatment-regimen estimand) | -28.7% at 68 wks (TRIUMPH-4) | -8% at 56 wks (SCALE) |
| FDA status (June 2026) | Approved (T2D, obesity, CVD, MASH, CKD, oral) | Approved (T2D, obesity) | Investigational - Phase 3 | Approved (Saxenda obesity, Victoza T2D) |
| CV outcomes data | Yes - SELECT (20% MACE drop) | Mounjaro label: major cardiovascular-event risk reduction in high-risk adults with T2D | Investigational; no approved cardiovascular indication | Yes - LEADER (13% MACE drop) |
These compounds are not interchangeable. Cross-trial results differ in population, duration, and estimand; they do not establish a ranking. Approved and investigational study products are not equivalent to research powders.
What sets each apart
- Semaglutide has the deepest evidence base across diabetes, obesity, heart, kidney, MASH, and oral. No other GLP-1 has six approved indications.
- Tirzepatide produced greater weight loss head-to-head in SURMOUNT-5: -20.2% vs -13.7%. The trial compared maximum-tolerated tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg weekly.
- Retatrutide has the highest observed weight loss to date but is still investigational. Glucagon agonism adds energy expenditure and liver-fat reduction signals.
- Liraglutide is older and less effective for weight loss but has long real-world history and may still fit specific clinical scenarios.
For non-GLP-1 metabolic alternatives, see the tesofensine protocol (triple monoamine reuptake inhibitor) or the MOTS-c protocol (mitochondrial peptide).
Semaglutide Blood Tests & Monitoring
Semaglutide is an approved GLP-1 receptor agonist used in diabetes and weight-management contexts. Monitoring focuses on glucose control, kidney context, lipids, GI symptoms, gallbladder/pancreas symptoms, and thyroid-history cautions.
Blood test markers to discuss with a clinician
Marker
A1c
Why it matters
Shows longer-term glucose control and helps track metabolic response over time.
Timing
Baseline
Marker
Fasting glucose
Why it matters
Gives a current glucose snapshot, especially when appetite and diabetes medication needs change.
Timing
Follow-up
Marker
Comprehensive metabolic panel (CMP)
Why it matters
Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration.
Timing
Baseline
Marker
Lipid panel
Why it matters
Tracks cardiometabolic changes during weight-loss or diabetes-management phases.
Timing
Follow-up
Marker
Blood pressure and resting heart rate
Why it matters
Adds cardiovascular context during weight loss, medication changes, and hydration shifts.
Timing
Optional
| Marker | Why it matters | Timing |
|---|---|---|
| A1c | Shows longer-term glucose control and helps track metabolic response over time. | Baseline |
| Fasting glucose | Gives a current glucose snapshot, especially when appetite and diabetes medication needs change. | Follow-up |
| Comprehensive metabolic panel (CMP) | Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration. | Baseline |
| Lipid panel | Tracks cardiometabolic changes during weight-loss or diabetes-management phases. | Follow-up |
| Blood pressure and resting heart rate | Adds cardiovascular context during weight loss, medication changes, and hydration shifts. | Optional |
Monitoring guidance is label-informed for semaglutide and supported by GLP-1 clinical monitoring considerations.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Beyond Whoosh
Pharmacy Grade Semaglutide
Prescription-grade peptide care through Beyond Whoosh. Whoosh prescribes after a clinician reviews your eligibility.
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before starting or changing dose, especially with diabetes, kidney disease, pancreatitis history, gallbladder history, thyroid cancer history, or major calorie restriction.
Follow-up
Repeat glucose and CMP-related markers after 4-12 weeks or sooner if vomiting, dehydration, or glucose symptoms occur.
Longer term
For ongoing use, review metabolic and kidney trends every 3-6 months with a clinician.
How to interpret the labs
- Diabetes medications may need clinician review if glucose drops with reduced intake.
- Severe abdominal pain, gallbladder symptoms, and persistent vomiting require symptom-based review.
- Personal or family history of medullary thyroid carcinoma or MEN2 is an important label-based caution.
Do not wait for routine labs
Severe abdominal pain, persistent vomiting, signs of dehydration, fainting, allergic symptoms, or severe low-glucose symptoms need medical review. A neck mass, trouble swallowing, or persistent hoarseness should be discussed with a clinician.
FAQ
Q1: What is the starting dose of semaglutide?
For Wegovy injection, the standard starting dose is 0.25 mg once weekly for four weeks, followed by four-week stages at 0.5, 1, and 1.7 mg toward the selected maintenance dose. Adult weight-reduction maintenance is 1.7 or 2.4 mg, with an optional later 7.2 mg increase under specific label conditions. Ozempic injection also starts at 0.25 mg, but uses different maintenance guidance. Oral products have separate daily doses and 30-day escalation stages.
Q2: What is semaglutide's half-life?
Semaglutide has a half-life of about 7 days (165-184 hours), among the longest for current GLP-1 receptor agonists. A fatty acid chain attached to the peptide binds to albumin in the blood, which slows clearance. The 7-day half-life supports once-weekly dosing and means it takes about 4-5 weeks at each dose level to reach steady state. After stopping, semaglutide remains in the body for roughly 5-7 weeks.
Q3: How much weight can you lose on semaglutide?
In the STEP 1 clinical trial (NEJM, 2021), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks (about 33.6 lbs from a 232 lb average baseline) vs 2.4% with placebo. 86.4% achieved at least 5% loss, and about one-third reached 20% or more. STEP 3 with intensive behavior therapy showed 16.0% loss. STEP 5 showed sustained 15.2% loss at 2 years. STEP 2 in type 2 diabetes showed 9.6% loss.
Q4: How do you reconstitute semaglutide?
Approved Ozempic and Wegovy injections are finished products; do not apply research-powder mixing instructions to them. For arithmetic only, a nominal 5 mg in a final 2.0 mL equals 2.5 mg/mL, where 0.25 mg equals 0.10 mL or 10 U-100 units. This does not validate a diluent, preparation method, sterility, stability, or suitability for human use. Use the Pep Pal calculator for nominal conversions.
Q5: Is semaglutide FDA-approved?
Yes. As of June 2026, semaglutide has broad FDA approval across multiple indications and brand names. Ozempic is approved for type 2 diabetes glycemic control (2017), cardiovascular risk reduction in T2D (2020), and CKD progression in T2D (January 2025). Wegovy is approved for chronic weight management (2021), cardiovascular risk reduction in adults with obesity and CVD (2024), and non-cirrhotic MASH with F2-F3 fibrosis (August 2025). The oral Wegovy 25 mg pill was approved in December 2025. Rybelsus is the older oral T2D form.
Q6: What are the most common side effects?
Stomach side effects are most common. In pooled STEP 1-3 data on the 2.4 mg dose, nausea occurred in 43.9% (vs 16.1% placebo), diarrhea in 29.7% (vs 15.9%), vomiting in 24.5% (vs 6.3%), and constipation in 24.2% (vs 11.1%). These were most frequent during dose escalation, peaked around weeks 8-20, and were usually mild-to-moderate and transient. Permanent discontinuation due to side effects was 6.8%. Semaglutide carries a boxed warning for thyroid C-cell tumors in rodent studies and is contraindicated in people with MTC or MEN 2.
Q7: How does semaglutide compare to tirzepatide and retatrutide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP agonist. Retatrutide is a triple GLP-1 + GIP + glucagon agonist. In SURMOUNT-5, maximum-tolerated tirzepatide 10/15 mg produced -20.2% weight loss vs -13.7% for maximum-tolerated semaglutide 1.7/2.4 mg at 72 weeks. Retatrutide Phase 3 reported up to -28.7% at 68 weeks. Semaglutide's strength is depth of outcomes evidence: SELECT cardiovascular data, FLOW kidney protection, MASH approval (ESSENCE), and oral formulations.
Q8: What vial sizes are available for research semaglutide?
Research suppliers list nominal 2, 3, 5, and 10 mg vials. Vial mass changes the concentration math and theoretical amount count, but it does not establish product identity, sterility, equivalence to approved semaglutide, or weeks of usable life. Actual quantities also depend on product-specific discard dates and losses.
Q9: How much bacteriostatic water should be added to semaglutide?
BAC water volume depends on vial size and desired concentration. For a 5 mg vial, 2.0 mL gives 2.5 mg/mL, where 0.25 mg = 10 units and 2.4 mg = 96 units on a U-100 syringe. For a 10 mg vial, 3.0 mL gives about 3.33 mg/mL, where 0.25 mg = 7.5 units and 2.4 mg = 72 units. A more concentrated 5 mg/mL option (5 mg in 1.0 mL) gives smaller draws but needs more precise syringe handling. Use the Pep Pal calculator for any custom setup.
Q10: What are the maximum approved semaglutide doses?
Approved limits depend on the exact product and indication. Wegovy injection may be increased to 7.2 mg weekly only for adult weight reduction, after at least four weeks tolerated at 2.4 mg when more weight reduction is clinically indicated. That option does not apply to pediatric, cardiovascular-risk, or MASH dosing. Ozempic injection has a 2 mg weekly maximum. Oral maxima are 25 mg daily for Wegovy, 14 mg for Rybelsus, and 9 mg for oral Ozempic; these formulations are not interchangeable milligram for milligram.
Q11: How should reconstituted semaglutide be stored?
No generic storage or beyond-use period for research semaglutide is established here. Use validated instructions for the exact material and formulation. Compounded preparations follow the dispensing pharmacy’s label; approved Ozempic and Wegovy products follow their own presentation-specific instructions. An opened water bottle has a separate discard date. Concentration math or a clear appearance does not establish stability or sterility.
Q12: Is Wegovy 25 mg the same as Rybelsus?
No. Wegovy tablets and Rybelsus contain semaglutide but have different formulations, indications, and daily doses. Wegovy uses 1.5, 4, and 9 mg in successive 30-day stages, then 25 mg from day 91. Rybelsus uses 3 mg for days 1–30, then 7 mg; from day 61, 14 mg is optional if more glycemic control is needed. Oral Ozempic is another separate 1.5/4/9 mg formulation. Do not substitute these products milligram for milligram.
Q13: Is semaglutide insulin?
No. Semaglutide is not insulin. It is a GLP-1 receptor agonist - a drug that copies the natural gut hormone GLP-1. It does cause the pancreas to release insulin, but only when blood sugar is already high (glucose-dependent insulin secretion). That is why semaglutide is much less likely to cause dangerous low blood sugar than direct insulin. Insulin works by directly adding the hormone insulin to the body. Semaglutide works by signaling the body to release its own insulin when it is needed.
Q14: Is there a generic semaglutide?
As of June 2026, no generic semaglutide is FDA-approved in the United States. Novo Nordisk still holds active patents. The FDA-recognized shortage of semaglutide ended in 2025, which narrowed the legal scope of 503A/503B compounded semaglutide. Some countries have different patent timelines, with generic semaglutide expected in Canada earlier than the US. Verify current status with FDA orange-book listings and country-specific regulators before relying on this answer.
Q15: Where can I calculate reconstitution and syringe units?
Use the Pep Pal calculator for exact dose-to-unit conversions. Enter vial size, BAC water volume, and target dose to get the matching syringe draw.
Q16: Where can I compare peptide suppliers?
Browse the PepPal supplier directory for current supplier listings, or read the PepPal supplier rankings for ranked comparisons with Finnrick testing context.
Sources & Research
- 1. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine (2025)
- 2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine (2021)
- 3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine (2023)
- 4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine (2016)
- 5. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine (2024)
- 6. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). New England Journal of Medicine (2025)
- 7. Wharton S, Calanna S, Davies M, et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity. Diabetes, Obesity and Metabolism (2022)
- 8. Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine (2022)
- 9. McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). New England Journal of Medicine (2025)
- 10. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity and Type 2 Diabetes (STEP 2). Lancet (2021)
- 11. U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets - Prescribing Information (June 2026). FDA (2026)
- 12. U.S. Food and Drug Administration. Ozempic (semaglutide) injection - Prescribing Information. FDA (2025)
- 13. Novo Nordisk / U.S. Food and Drug Administration Rybelsus and Ozempic (semaglutide) tablets - Current Prescribing Information. DailyMed (2026)
- 14. ClinicalTrials.gov. STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering from Overweight or Obesity (NCT03548935). ClinicalTrials.gov (2018)
Related Dosing Protocols
Educational use only
This guide is an educational research reference, not medical advice or a treatment plan. Semaglutide is FDA-approved under Ozempic, Wegovy, and Rybelsus for specific indications. Research-grade lyophilized semaglutide discussed in reconstitution sections is for research use only. Consult a qualified clinician before considering any peptide protocol.
Calculate vial math
Use the calculator for custom vial size, BAC water volume, and syringe-unit math.
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: October 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page
See our research first on Google
Add us as a preferred source for Top Stories.